SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Blomqvist Carl) "

Sökning: WFRF:(Blomqvist Carl)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Blomqvist, Carl Oliver, 1984-, et al. (författare)
  • Naming and multilingualism – Personal designations in medieval Finnish charters
  • 2015
  • Ingår i: NAME AND NAMING Proceedings of the Third International Conference on Onomastics “Name and Naming” Conventional / Unconventional in Onomastics. - Cluj-Napoca : Editura argonaut.
  • Konferensbidrag (övrigt vetenskapligt)abstract
    • This paper aims to analyze Swedish-Finnish mixed-language personal designations in medieval charters from Finland from the perspective of code-switching. A data set of 718 locative adverbials containing Finnish toponyms is related to empirical findings in the morphosyntax of modern Finnish-English code-switching. I argue that the morphosyntactic marking of Finnish toponyms in the medieval charters is concordant with syntactic patterns in modern code-switching. In earlier scholarship, this language-mixing was thought to be the result of linguistic confusion. The present results would indicate that the medieval scribes of Finland in fact were fluent code-switchers that used multilingual resources to their advantage.
  •  
2.
  • Hakamies-Blomqvist, Liisa, et al. (författare)
  • Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil : A multicentre randomised phase III trial by the Scandinavian breast group
  • 2000
  • Ingår i: European Journal of Cancer. - 0959-8049 .- 1879-0852. ; 36:11, s. 1411-7
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of this study was to evaluate the effects of two alternative chemotherapy regimes on the quality of life (QoL) of patients with advanced breast cancer. In a multicentre trial, 283 patients were randomised to receive either docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). QoL was assessed at baseline and before each treatment using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). Initial compliance in the QoL study was 96% and the overall compliance 82%. QoL data were available for 245 patients (T 130 and 115 MF). Both treatment groups showed some improvement in emotional functioning during treatment, with a significant difference favouring the MF group at treatment cycles 5 and 6. In the T group, the scores on the other functional scales remained stable throughout the first six cycles. There were significant differences favouring the MF group on the social functioning scale at treatment cycle 6 and on the Global QoL scale at treatment cycles 5 and 6. On most symptom and single-item scales there were no statistically significant differences between the groups. However, at baseline, the T patients reported more appetite loss, at treatment cycles 2-4, the MF patients reported more nausea/vomiting, and at treatment cycle 6, the T patients reported more symptoms of fatigue, dyspnoea and insomnia. There were no statistically significant differences between the groups in the mean change scores of the functional and symptom scales. Interindividual variance was, however, larger in the T group. Differences in QoL between the two treatment groups were minor. Hence, given the expectancy of comparable QoL outcomes, the choice of treatment should be made on the basis of the expected clinical effect.
  •  
3.
  • Hakamies-Blomqvist, Liisa, et al. (författare)
  • Timing of quality of life (QoL) assessments as a source of error in oncological trials
  • 2001
  • Ingår i: Journal of Advanced Nursing. - 0309-2402 .- 1365-2648. ; 35:5, s. 709-16
  • Tidskriftsartikel (refereegranskat)abstract
    • AIM OF THE STUDY: To produce an empirical estimate of the nature and magnitude of the error produced by incorrect timing quality of life (QoL) measurements in patients receiving chemotherapy. DESIGN: In a multicentre trial, 283 patients were randomized to receive either docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). The QoL was assessed at baseline and before each treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). The study design was retrospective. Data were analysed using t-tests. RESULTS: Erroneous timing affected the QoL findings in both treatment arms. At baseline, there were statistically significant differences in the MF group on the nausea/vomiting scale, with ill-timed assessment showing more symptoms, and in the T group on the physical functioning scale with ill-timed assessments indicating better QoL. The mean scores of correct vs. incorrect timings over the first 14 cycles showed statistically significant differences on several scales. In the MF group, ill-timed assessments indicated significantly worse physical functioning and global QoL, and significantly more of the following symptoms: fatigue, nausea/vomiting, insomnia, appetite loss, and constipation. In the T group, ill-timed assessment showed better physical functioning, less dyspnoea and more insomnia than correctly timed assessments. The reasons for erroneous timing were not always detectable retrospectively. However, in some cases the MF group, being in standard treatment, seemed to have followed a clinical routine not involving the active participation of the study nurse responsible, whereas patients in the experimental T group were more consistently taken care of by the study nurses. CONCLUSIONS: Incorrect timing of QoL assessments in oncological trials jeopardises both the reliability of the QoL findings within treatment and the validity of QoL outcome comparisons between treatments. This issue should be emphasized in the planning of both the study design and clinical routines.
  •  
4.
  •  
5.
  • Luoma, Minna-Liisa, et al. (författare)
  • Physical performance, toxicity, and quality of life as assessed by the physician and the patient
  • 2002
  • Ingår i: Acta Oncol. - 0284-186X (Print). ; 41:1, s. 44-9
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to study the relationship between physician-assessed quality of life parameters, i.e., toxicity and physical performance, and patients' self-reports of their quality of life (QoL). QoL was assessed at baseline and before each treatment, using the EORTC QLQ-C30. The WHO performance score (PS) and toxicity were assessed in physician interviews. The correlations between the WHO PS and the QLQ-C30 functioning scale scores varied from weak to moderate, depending on the scale. Strongest associations were found in physical-, social-, and role functioning, and in the global QoL. The QLQ-C30 nausea/vomiting and diarrhea scales correlated moderately to corresponding WHO scores. A multiple linear regression analysis was used to analyze the contribution of WHO PS and toxicity variables to the global QoL. The best model explained only 16% of the variance of the global QoL score. The present findings highlight the importance of independent QoL assessments focused on those aspects of QoL not captured in clinical interviews with the physician.
  •  
6.
  • Luoma, Minna-Liisa, et al. (författare)
  • Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
  • 2003
  • Ingår i: European Journal of Cancer. - IFAC & Elsevier Ltd.. - 1879-0852. ; 39:10, s. 1370-1376
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of the study was to investigate whether baseline quality of life (QoL) and changes in QoL scores from baseline are prognostic for time to progression (TTP) and/or overall survival (OS) in patients with advanced breast cancer receiving docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). QoL was assessed at baseline and before each treatment using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). Survival curves and probabilities were estimated using the Kaplan-Meier technique. The Cox proportional hazards regression model was used for both the univariate and multivariate analyses to explore relationships between baseline QoL variables and TTP, as well as OS. In the univariate analysis, more severe pain and fatigue at baseline were predictive for a shorter OS; global QoL, physical functioning and appetite loss had a borderline significance (P=0.0130 for global QoL; P=0.0256 for physical functioning: P=0.0149 for appetite loss). World Health Organization (WHO) performance status was significantly predictive for OS. In the multivariate analysis, more severe pain at baseline was predictive for a shorter OS. In contrast, baseline QoL had no prognostic value for the duration of TTP. QoL change scores from baseline QoL predicted neither OS nor TTP. Our findings suggest that while QoL measurements are important in evaluating patients' QoL, they have no great importance in predicting primary clinical endpoints such as TTP or OS in advanced breast cancer patients. (C) 2002 Elsevier Science Ltd. All rights reserved.
  •  
7.
  • Wallman, Carl-Gustaf, et al. (författare)
  • Tema Vintermodell etapp 2, huvudrapport
  • 2006
  • Rapport (övrigt vetenskapligt)abstract
    • Syftet med Vintermodellen är att beräkna och värdera de väsentligaste konsekvenserna för trafikanter, väghållare och samhälle av olika strategier och åtgärder inom vinterväghållningen. Huvudrapporten är i sig en sammanfattning av de rapporter som beskriver Vintermodellens olika delmodeller. Navet i Vintermodellen är Väglagsmodellen, som utgående från väderdata, vidtagna väghållningsåtgärder och trafik beräknar väglaget timme för timme under vintersäsongen. Väglagsmodellen styr beräkningarna i de olika effektmodellerna: Olycksmodellen, Framkomlighetsmodellen, Fordonskostnadsmodellen, Miljömodellen och Modellen för väghållarkostnader. I Olycksmodellen beräknas olyckskvoter, olyckstyper och konsekvenser, allt kopplat till olika väglag och deras varaktigheter.I Framkomlighetsmodellen beräknas olika väglags effekt på medelhastigheter och restider.I Fordonskostnadsmodellen beräknas kostnader för bränsleförbrukning och korrosion på grund av vägsalt.I Miljömodellen beräknas konsekvenserna för vägnära vegetation av vägsalt.I Modellen för väghållarkostnader beräknas dels direkta kostnader för åtgärderna, dels kostnader för skador och slitage på beläggning, vägmarkeringar etc. som följd av vinterväghållningsåtgärder.
8.
  • Aaltonen, Kirsimari, et al. (författare)
  • Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer
  • 2009
  • Ingår i: Breast Cancer Research and Treatment. - Springer. - 1573-7217. ; 113:1, s. 75-82
  • Tidskriftsartikel (refereegranskat)abstract
    • Cyclins D1 and E play an important role in breast carcinogenesis. High cyclin E expression is common in hormone receptor negative and high grade aggressive breast cancer, whereas cyclin D1 in hormone receptor positive and low grade breast cancer. Experimental data has suggested that cyclin D1 and E mediate cell proliferation by different mechanisms in estrogen receptor (ER) positive and negative breast cancer. To test this hypotheses in large breast cancer material and to clarify the histopathological correlations of cyclin E and D1, especially the association with proliferation, we analyzed cyclin E and D1 immunohistochemical expression on breast tumour microarrays consisting of 1348 invasive breast cancers. High cyclin D1 expression was associated with high grade (P < 0.0005), high cyclin A (P < 0.0005) and Ki67 (P < 0.0005) expression among ER positive but with low grade (P = 0.05) and low Ki67 (P = 0.01) expression among ER negative breast cancers. Cyclin E and D1 expression correlated positively in ER positive (P < 0.0005) but had a negative correlation in ER negative tumours (P = 0.004). Cyclin E associated with high grade among all tumours (P < 0.0005). In conclusion, the findings of this study show that cyclin D1 has separate roles, and proliferation is driven by different mechanisms in ER positive and negative breast cancers.
  •  
9.
  • Aaltonen, Kirsimari, et al. (författare)
  • Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers
  • 2008
  • Ingår i: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 14:7, s. 1976-83
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: We analyzed the expression of critical cell cycle regulators cyclin E and cyclin D1 in familial breast cancer, focusing on BRCA mutation-negative tumors. Cyclin E expression in tumors of BRCA1 or BRCA2 carriers is higher, and cyclin D1 expression lower, than in sporadic tumors. In familial non-BRCA1/2 tumors, cyclin E and cyclin D1 expression has not been studied. EXPERIMENTAL DESIGN: Cyclin E and cyclin D1 immunohistochemical expression was studied in tissue microarrays consisting of 53 BRCA1, 58 BRCA2, 798 familial non-BRCA1/2, and 439 sporadic breast tumors. RESULTS: In univariate analysis, BRCA1 tumors had significantly more frequently high cyclin E (88%) and low cyclin D1 (84%) expression than sporadic (54% and 49%, respectively) or familial non-BRCA1/2 (38% and 45%, respectively) tumors. BRCA2 tumors had significantly more frequently low cyclin D1 expression (68%) than sporadic or familial non-BRCA1/2 tumors and significantly more frequently high cyclin E expression than familial non-BRCA1/2 tumors. In a logistic regression model, cyclin expression, early age of onset, and estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) status were the independent factors most clearly distinguishing tumors of BRCA1 mutation carriers from other familial breast cancers. High cyclin E and low cyclin D1 expression were also independent predictors of BRCA2 mutation when compared with familial non-BRCA1/2 tumors. Most interestingly, lower frequency of high cyclin E expression independently distinguished familial non-BRCA1/2 tumors also from sporadic ones. CONCLUSIONS: Cyclin E and cyclin D1 expression distinguishes non-BRCA1/2 tumors from both sporadic and BRCA1- and BRCA2-associated tumors and may reflect different predisposition and pathogenesis in these groups.
  •  
10.
  • Aaltonen, Kirsimari, et al. (författare)
  • High cyclin B1 expression is associated with poor survival in breast cancer
  • 2009
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 100:7, s. 1055-60
  • Tidskriftsartikel (refereegranskat)abstract
    • Cyclin B1 regulates the G(2)-M transition of the cell cycle. Cyclin B1 expression is higher in premalignant and malignant than normal breast lesions. Correlation of cyclin B1 expression with other histopathological variables and prognostic role in breast cancer are not fully understood. Traditionally used prognostic criteria identify large subset of patients to receive adjuvant chemotherapy and to be exposed to adverse effects. A reliable and simple method helping prognostic evaluation in breast cancer is needed. We analysed cyclin B1 expression on 1348 invasive breast cancers and studied correlations with other histopathological variables and survival. High cyclin B1 correlated with high tumour grade, large tumour size and positive nodal status, oestrogen and progesterone receptor negativity, positive HER2 and p53 status, young age at diagnosis, and high cyclin E, cyclin A and Ki67 expression. Among patients not given adjuvant chemotherapy high cyclin B1 was a strong predictor of shorter overall and metastasis-free survival (RR 3.74, P&lt;0.0005 and RR 3.51, P&lt;0.0005, respectively), and remained as an independent prognostic factor also in multivariate analysis (RR 1.80, P=0.04 and RR 2.31, P=0.02, respectively). This study suggests high cyclin B1 associates with aggressive phenotype and is an independent prognostic factor in breast cancer.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (36)
Typ av publikation
tidskriftsartikel (144)
rapport (4)
konferensbidrag (4)
annan publikation (4)
bok (3)
doktorsavhandling (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (133)
övrigt vetenskapligt (26)
populärvet., debatt m.m. (1)
Författare/redaktör
Blomqvist, Carl, (140)
Nevanlinna, Heli (65)
Aittomäki, Kristiina (35)
Chang-Claude, Jenny (30)
Brauch, Hiltrud (30)
Mannermaa, Arto (30)
visa fler...
Garcia-Closas, Monts ... (29)
Hamann, Ute (29)
Giles, Graham G (28)
Hopper, John L. (27)
Kosma, Veli-Matti (27)
Hall, Per (27)
Cox, Angela (27)
Schmidt, Marjanka K. (26)
Czene, Kamila (26)
Fasching, Peter A. (26)
Winqvist, Robert (26)
Easton, Douglas F. (25)
Couch, Fergus J. (25)
Peto, Julian (24)
Milne, Roger L. (24)
Anton-Culver, Hoda (24)
Andrulis, Irene L. (24)
Dunning, Alison M. (24)
Guenel, Pascal (24)
Bojesen, Stig E. (24)
Beckmann, Matthias W ... (24)
Lambrechts, Diether (24)
Benitez, Javier (23)
Margolin, Sara (23)
Amini, Rose-Marie, (22)
Brenner, Hermann (22)
Southey, Melissa C. (22)
Burwinkel, Barbara (22)
Lindblom, Annika (22)
Flesch-Janys, Dieter (22)
Wang, Qin (21)
Devilee, Peter (21)
González-Neira, Anna (21)
Meindl, Alfons (21)
Olson, Janet E. (21)
Pharoah, Paul D. P. (21)
Bolla, Manjeet K. (21)
Michailidou, Kyriaki (21)
Haiman, Christopher ... (20)
Fletcher, Olivia (20)
Flyger, Henrik (20)
Chenevix-Trench, Geo ... (20)
Radice, Paolo (20)
Cross, Simon S. (20)
visa färre...
Lärosäte
Uppsala universitet (122)
Karolinska Institutet (54)
Lunds universitet (47)
Umeå universitet (18)
Örebro universitet (8)
Linköpings universitet (7)
visa fler...
Göteborgs universitet (6)
Chalmers tekniska högskola (6)
RISE (4)
Stockholms universitet (2)
VTI - Statens väg- och transportforskningsinstitut (2)
Högskolan i Jönköping (1)
visa färre...
Språk
Engelska (141)
Svenska (12)
Odefinierat språk (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (127)
Naturvetenskap (8)
Teknik (6)
Humaniora (6)
Samhällsvetenskap (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy